Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A known ✓ | Q03164 | 3/20 | 0.39 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.39 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL2778279 | 1.00 | MEN1 (0.39) | MEN1KMT2AUSP2PPARGKEAP1 | |
| SCHEMBL309794 | 0.85 | MAPT (0.50) | MEN1KMT2AUSP2PPARGKEAP1 | |
| SCHEMBL1290735 | 0.76 | ALOX5 (0.46) | KMT2AHSD17B10MAPTTRPA1ALDH1A1 | |
| SCHEMBL14128978 | 0.71 | TRPA1 (0.44) | MEN1KMT2AUSP2PPARGKEAP1 | |
| SCHEMBL5138230 | 0.71 | TRPA1 (0.47) | MEN1KMT2AUSP2PPARGKEAP1 | |
| SCHEMBL4970782 | 0.69 | TRPA1 (0.38) | MEN1KMT2AUSP2PPARGKEAP1 | |
| SCHEMBL11499806 | 0.68 | GAA (0.43) | MEN1KMT2AUSP2PPARGKEAP1 | |
| SCHEMBL20067134 | 0.68 | ROS1 (0.42) | MEN1KMT2AUSP2PPARGKEAP1 | |
| SCHEMBL8203995 | 0.68 | BCHE (0.44) | MEN1KMT2AUSP2PPARGKEAP1 | |
| SCHEMBL3521082 | 0.68 | DRD2 (0.43) | MEN1KMT2AHSD17B10MAPTTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2218442-A1 | Methods, compositions, and kits for the treatment of ophthalmic disorders | CombinatoRx, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20090075951-A1 | Methods and Reagents for the Treatment of Inflammatory Disorders | COMBINATORX, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090005358-A1 | Compositions and methods for treating medical conditions | LG CHEM, LTD. (KR) | 2009-01-01 | — | — | US | disclosed |
| WO-2009002507-A1 | COMPOSITIONS AND METHODS FOR TREATING MEDICAL CONDITIONS | COMBINATORX, INCORPORATED (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20080280862-A1 | Methods, compositions, and kits for the treatment of pain | COMBINATORX, INCORPORATED | 2008-11-13 | — | — | US | disclosed |
| EP-1956906-A2 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MEDICAL CONDITIONS | CombinatoRx, Incorporated (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008085927-A2 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF PAIN | COMBINATORX, INCORPORATED (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| EP-1691744-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CombinatoRx, Incorporated (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1675550-A2 | THERAPEUTIC REGIMENS FOR ADMINISTERING DRUG COMBINATIONS | CombinatoRx, Incorporated (US) | 2006-07-05 | — | — | EP | disclosed |
| EP-1599212-A4 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1599212-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050187200-A1 | Methods and reagents for the treatment of inflammatory disorders | COMBINATORX, INCORPORATED | 2005-08-25 | — | — | US | disclosed |
| WO-2005048927-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20050112199-A1 | Therapeutic regimens for administering drug combinations | COMBINATORX, INCORPORATED | 2005-05-26 | — | — | US | disclosed |
| WO-2005030132-A2 | THERAPEUTIC REGIMENS FOR ADMINISTERING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED | 2004-11-11 | — | — | US | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005358-A1 | Compositions and methods for treating medical conditions | ITCH, TSLP, P2RX5 | MEN1 2256/4885KMT2A 1105/4885PPARG 2141/4885 |
| US-20080280862-A1 | Methods, compositions, and kits for the treatment of pain | ACHE, MPO, P2RX3 | MEN1 4669/4885KMT2A 2859/4885PPARG 2075/4885 |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | MEN1 3638/4885KMT2A 1108/4885PPARG 3661/4885 |
| US-20050187200-A1 | Methods and reagents for the treatment of inflammatory disorders | IL5, TNF, LTC4S | MEN1 3022/4885KMT2A 3939/4885PPARG 471/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | MEN1 4701/4885KMT2A 2353/4885PPARG 1151/4885 |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | HLA-DRB1, TSLP, SERPINA6 | MEN1 3969/4885KMT2A 4265/4885PPARG 1220/4885 |
| US-20090075951-A1 | Methods and Reagents for the Treatment of Inflammatory Disorders | IL5, TNF, LTC4S | MEN1 3022/4885KMT2A 3939/4885PPARG 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.